Specialty Pharma Journal Specialty, Precision & Technology
US health regulators granted orphan drug designation to Calgary-based Oncolytics Biotech’s lead brain tumor candidate. The company announced that the US Food and Drug Administration (FDA) granted orphan status to its Reolysin for treatment of malignant glioma. Oncolytics said that it had applied for orphan designation for pediatric high grade …
Tag Archives: oncolytics biotech inc.
April, 2015
March, 2015
-
3 March
Oncolytics’ Reolysin Receives Orphan Drug Designations from the FDA
Oncolytics Biotech Inc.’s lead product candidate Reolysin was granted orphan drug designation for two types of cancer this week. The company announced Monday that the US Food and Drug Administration (FDA) granted the drug orphan drug designation for Reolysin for the treatment of cancer of the fallopian tube. On Tuesday, …
February, 2015
-
17 February
FDA Grants Oncolytics’ Pancreatic Cancer Drug Orphan Drug Designation
Today, Oncolytics Biotech Inc. announced that its lead pancreatic cancer drug was granted orphan drug designation by US health regulators. The company said that its lead product candidate, Reolysin, was granted orphan drug status by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The agency provides …